Parravicini Chiara, Abbracchio Maria P, Fantucci Piercarlo, Ranghino Graziella
Department of Pharmacological Sciences, University of Milano, via Balzaretti 9, 20133 Milano, Italy.
BMC Struct Biol. 2010 Mar 16;10:8. doi: 10.1186/1472-6807-10-8.
GPR17 is a hybrid G-protein-coupled receptor (GPCR) activated by two unrelated ligand families, extracellular nucleotides and cysteinyl-leukotrienes (cysteinyl-LTs), and involved in brain damage and repair. Its exploitment as a target for novel neuro-reparative strategies depends on the elucidation of the molecular determinants driving binding of purinergic and leukotrienic ligands. Here, we applied docking and molecular dynamics simulations (MD) to analyse the binding and the forced unbinding of two GPR17 ligands (the endogenous purinergic agonist UDP and the leukotriene receptor antagonist pranlukast from both the wild-type (WT) receptor and a mutant model, where a basic residue hypothesized to be crucial for nucleotide binding had been mutated (R255I) to Ile.
MD suggested that GPR17 nucleotide binding pocket is enclosed between the helical bundle and extracellular loop (EL) 2. The driving interaction involves R255 and the UDP phosphate moiety. To support this hypothesis, steered MD experiments showed that the energy required to unbind UDP is higher for the WT receptor than for R255I. Three potential binding sites for pranlukast where instead found and analysed. In one of its preferential docking conformations, pranlukast tetrazole group is close to R255 and phenyl rings are placed into a subpocket highly conserved among GPCRs. Pulling forces developed to break polar and aromatic interactions of pranlukast were comparable. No differences between the WT receptor and the R255I receptor were found for the unbinding of pranlukast.
These data thus suggest that, in contrast to which has been hypothesized for nucleotides, the lack of the R255 residue doesn't affect the binding of pranlukast a crucial role for R255 in binding of nucleotides to GPR17. Aromatic interactions are instead likely to play a predominant role in the recognition of pranlukast, suggesting that two different binding subsites are present on GPR17.
GPR17是一种杂合G蛋白偶联受体(GPCR),可被两个不相关的配体家族激活,即细胞外核苷酸和半胱氨酰白三烯(cysteinyl-LTs),并参与脑损伤和修复。将其开发为新型神经修复策略的靶点取决于对驱动嘌呤能和白三烯配体结合的分子决定因素的阐明。在此,我们应用对接和分子动力学模拟(MD)来分析两种GPR17配体(内源性嘌呤能激动剂UDP和白三烯受体拮抗剂普仑司特)与野生型(WT)受体和突变模型的结合及强制解离,在该突变模型中,一个假定对核苷酸结合至关重要的碱性残基已被突变为异亮氨酸(R255I)。
MD表明,GPR17核苷酸结合口袋被封闭在螺旋束和细胞外环(EL)2之间。驱动相互作用涉及R255和UDP磷酸基团。为支持这一假设,引导MD实验表明,WT受体解离UDP所需的能量高于R255I。相反,发现并分析了普仑司特的三个潜在结合位点。在其一种优先对接构象中,普仑司特四唑基团靠近R255,苯环位于GPCR中高度保守的一个亚口袋中。为破坏普仑司特的极性和芳香相互作用而产生的拉力相当。在普仑司特的解离方面,未发现WT受体和R255I受体之间存在差异。
因此,这些数据表明,与核苷酸的假设情况相反,R255残基的缺失并不影响普仑司特的结合,R255在核苷酸与GPR17结合中起关键作用。相反,芳香相互作用可能在普仑司特的识别中起主要作用,这表明GPR17上存在两个不同的结合亚位点。